Neupulse Raises £3 Million to Accelerate Delivery of its Neurotherapeutic Technology

• Funding led by Eos Advisory and Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, signals strong investor confidence despite challenging market conditions.

Nottingham, UK – Thursday 12^th February 2026 / Sciad Communications / Neupulse, a neurotherapeutics company focused on delivering innovative solutions to people with brain health conditions, like Tourette Syndrome, has announced it has successfully raised £3 million in new funding.

The round was led by Eos Advisory and the Midlands Engine Investment Fund II, through appointed fund manager Mercia Ventures, with participation from existing and new investors.

The funding will be used to scale sales and accelerate Neupulse’s path to market, supporting product development, regulatory progress and early commercialisation, to ensure the company’s technology reaches individuals who need it most.

The funding comes at a time when venture and growth funding remains highly constrained, underscoring the strength of Neupulse’s proposition and the confidence investors have in both the company’s mission and execution. Neupulse’s continued momentum highlights growing demand for effective, clinically grounded neurotherapeutic solutions and positions Neupulse strongly for its next phase of growth.

Neupulse’s product is designed to address critical gaps in current treatment options, combining scientific rigour with a clear focus on real-world impact. This funding round enables the company to move decisively from development towards commercial launch in mid-2026, while continuing to build the evidence base required by clinicians, regulators, and healthcare systems.

The company first secured funding from the Midlands Engine Investment Fund II in 2024 to finalise development of a non-drug treatment to help manage the symptoms of Tourette’s Syndrome. The £500,000 investment helped Neupulse’s continued research into the TS therapy wristband device and clinical trials.

Eos and Mercia Ventures are both experienced backers of high-growth healthcare and deep-tech businesses, bringing not only capital but strategic expertise to support Neupulse. Their continued leadership reflects a shared belief in the company’s long-term potential and its ability to generate both commercial and clinical value.

Paul Cable, CEO, Neupulse said: “This investment underlines the unmet need in providing people with conditions like Tourette Syndrome a solution to manage their condition, and as a company, we are driven to improve the lives of individuals with these conditions.”

Ian Rhodes, Chair of the board at Neupulse, added: “This is a great example of advanced biomedical research from a leading UK university creating an initial UK market launch during 2026. This will increasingly benefit the UK economy as the technology scales out globally.”

David Tindall, Senior Investment Manager at the British Business Bank, said: “Neupulse’s growth over the past year, following investment from the Midlands Engine Investment Fund II, has been impressive. By addressing a clear gap in the market and delivering a much-needed solution for those affected, the business exemplifies the Fund’s commitment to backing ambitious, high-growth companies. This latest round of funding will further support Neupulse in developing and launching new treatment options.”

Andrew McNeill, Investor Director at Eos, said: “We are delighted to support the next chapter of Neupulse as they move towards commercialisation. This is exactly the kind of company and science we like to back. Passionate founders and technology with the potential to positively impact the lives of people across the globe.”

Sandy Reid, Fund Principal, Mercia Ventures added: “Tourette Syndrome is believed to affect up to two per cent of all children worldwide but currently the only treatments are medication and behavioural therapy, neither of which are ideal solutions. Neupulse’s device offers a genuine alternative that could transform lives.”

The £400m Midlands Engine Investment Fund II covers the entire Midlands region and provides debt finance from £25k to £2m and equity investment up to £5m to help a range of small and medium sized businesses to start up, scale up or stay ahead. The purpose of the Midlands Engine Investment Fund II is to drive sustainable economic growth by supporting innovation and creating local opportunity for new and growing businesses across the Midlands. The Midlands Engine Investment Fund II will increase the supply and diversity of early-stage finance for smaller businesses in the Midlands, providing funds to firms that might otherwise not receive investment and help to break down barriers in access to finance.

ENDS

For further information, please contact:

​Ben Garland 
Ecommere Operations Officer
Neupulse
E: press@neupulse.co.uk
T: +44 (0)7797838127

Sciad Communications, Media Relations
Juliette Craggs
E: pressteam@sciad.com
T: +44 (0)2034057892

Notes for Editors

Neurotherapeutics Ltd was founded in 2021 as a spin-out from the University of Nottingham, commercialising the research of Professor Stephen Jackson, Professor Georgina Jackson and Dr Barbara Morera.

We are a neurotechnology company pioneering non-invasive neuromodulation solutions to improve quality of life for people living with neurological and mental health conditions. Combining neuroscience and user-centric design, Neupulse develops wearable technologies that deliver effective and drug free solutions. Our mission is to make our neuromodulation therapies available to everyone, empowering individuals to take control of their neurological health.

About Mercia Ventures

Mercia Ventures is a proactive venture capital investor focused on being the first-choice partner for growth. Mercia Ventures makes equity investments of up to £10million across all sectors, with specialisms in Software, Consumer, Healthcare and Deep Tech.

Mercia Ventures is a trading name of investment funds managed by Mercia Fund Management Limited and Mercia Regional Ventures Limited, part of the Mercia Asset Management PLC Group, and sits alongside the Group’s wider private equity, debt and proprietary balance sheet operations. The Group has 11 offices in the UK, and Mercia Ventures’ national footprint and 48 strong investment team draws on their experiences as founders, PhD scientists, software engineers, corporate financiers and management consultants to help our partner companies successfully achieve their ambitions. Mercia Asset Management PLC has c.£2 billion of assets under management. Mercia Asset Management PLC is quoted on AIM with the epic “MERC”.

The Group raises its own Venture Capital Trusts (VCTs) and Enterprise Investment Scheme (EIS) Funds, and details about open offers can be found through Mercia’s website.

Mercia Asset Management PLC is quoted on AIM with the epic “MERC” and includes the following wholly owned subsidiaries:

• Mercia Fund Management Limited is authorised and regulated by the FCA under firm reference number 524856
• Mercia Regional Ventures Limited is authorised and regulated by the FCA under firm reference number 183363
• Mercia Business Loans Limited is authorised and regulated by the FCA under firm reference number 443560
• Frontier Development Capital Limited is authorised and regulated by the FCA under firm reference number 829697

www.mercia.co.uk

About the Midlands Engine Investment Fund II

• Operated by the British Business Bank, the Midlands Engine Investment Fund II (MEIF II) provides a mix of debt and equity funding. MEIF II offers a range of commercial finance options with small loans from £25k to £100k, debt finance from £100k to £2m and equity investment up to £5 million. It works alongside the Combined Authorities, Local Enterprise Partnerships (LEPs), and Growth Hubs, as well as local intermediaries such as accountants, fund managers and banks, to support smaller businesses in the Midlands at all stages of their development.
• The funds in which the MEIF II invests are open to businesses with material operations, or planning to open material operations, in the West and East and South East Midlands.
• Supported by Nations and Regions Investments Limited, a subsidiary of British Business Bank plc, the Bank is a development bank wholly owned by HM Government. Neither Nations and Regions Investments Limited nor British Business Bank plc are authorised or regulated by the Prudential Regulation Authority (PRA) or the Financial Conduct Authority (FCA).
• For investment by MEIF II sub-fund at the investee company level

The investment from the Midlands Engine Investment Fund II into Neupulse does not amount to any endorsement or warranty from Nations and Regions Investments Limited, the British Business Bank plc or the government of the United Kingdom.

​

​About Eos Advisory

Eos Advisory invests in and commercialises science and technology at local seed-stage, with the potential to scale globally, and with a focus on improving the health of people and the planet. Founded in St. Andrews in 2014, Eos is the trusted link between non-specialist Investors and highly specialist, knowledge intensive technology companies, building a portfolio of companies developing innovations to improve disease diagnostics, prevention, and treatment, environmental sustainability, and food and water security. Eos works in partnership with family offices, individuals, companies, and institutional investors who invest through an annual, EIS qualifying Innovation Fund, and an Investment Syndicate: https://eos-advisory.com